Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy

Annals of Surgical Oncology

Volumn 20, Issue 4, 2013, Pages 1101-1104

  Leinwand, Joshua C ^a   Bates, Gleneara E ^a   Allendorf, John D ^a   Chabot, John A ^a   Lewin, Sharyn N ^a   Taub, Robert N ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; OXALIPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD SAMPLING; BODY SURFACE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MALE; SPECTROPHOTOMETRY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASCITIC FLUID; BODY SURFACE AREA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROGNOSIS; PSEUDOMYXOMA PERITONEI; SERUM ALBUMIN, BOVINE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 84875217766     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2790-8     Document Type: Conference Paper

References (16)

1. D Elias T Matsuhisa L Sideris 2004 Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance Ann Oncol. 15 1558 1565 15367418 10.1093/annonc/mdh398 1:STN:280:DC%2BD2cvlvVKjug%3D%3D
2. RL Dedrick CE Myers PM Bungay VT DeVita Jr 1978 Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep. 62 1 11 626987 1:CAS:528:DyaE1cXhsVGqs78%3D
3. E Jerremalm M Hedeland I Wallin U Bondesson H Ehrsson 2004 Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex Pharm Res. 21 891 894 15180350 10.1023/B:PHAM.0000026444.67883.83 1:CAS:528:DC%2BD2cXjs1Kjuro%3D
4. H Mahteme I Wallin B Glimelius L Påhlman H Ehrsson 2008 Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion Eur J Clin Pharmacol. 64 907 911 18563401 10.1007/s00228-008-0511-9 1:CAS:528:DC%2BD1cXhtVKju7bL
5. LB Mongero JR Beck RM Kroslowitz M Argenziano JA Chabot 1999 Treatment of primary peritoneal mesothelioma by hyperthermic intraperitoneal chemotherapy Perfusion. 14 141 145 10338326 10.1177/026765919901400208 1:STN:280: DyaK1M3mvVKnug%3D%3D
6. JH Stewart 4th P Shen G Russell J Fenstermaker L McWilliams FM Coldrun, et al. 2008 A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers Ann Surg Oncol. 15 2137 2145 18493824 10.1245/s10434-008-9967-1
7. Y Wang J Moss R Thisted 1992 Predictors of body surface area J Clin Anesth. 4 4 10 1540367 10.1016/0952-8180(92)90111-D 1:STN:280: DyaK387nt1Cgtg%3D%3D
8. PH Sugarbaker KA Jablonski 1995 Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy Ann Surg. 221 124 132 7857141 10.1097/00000658-199502000-00002 1:STN:280:DyaK2M7mtVGnsA%3D%3D
9. P Jacquet JS Jelinek D Chang P Koslowe PH Sugarbaker 1995 Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery J Am Coll Surg. 181 530 538 7582228 1:STN:280:DyaK28%2FpsFWguw%3D%3D
10. RJ Baker DD Kozoll KA Meyer 1957 The use of surface area as a basis for establishing normal blood volume Surg Gynecol Obstet. 104 183 189 13422132 1:STN:280:DyaG2s%2FmvVGlsg%3D%3D
11. P Keshaviah PF Emerson EF Vonesh JC Brandes 1994 Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis J Am Soc Nephrol. 4 1820 1826 8068881 1:STN:280:DyaK2czksl2qug%3D%3D
12. GR DeFoe CS Ross EM Olmstead SD Surgenor MP Fillinger RC Groom, et al. 2001 Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group Ann Thorac Surg. 71 769 776 11269449 10.1016/S0003-4975(00)02393-6 1:STN:280:DC%2BD3M7mvVWjug%3D%3D
13. Vazquez V de Lima OA Stuart F Mohamed PH Sugarbaker 2003 Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics Cancer Chemother Pharmacol. 52 108 112 10.1007/s00280-003-0626- 8
14. D Elias M Bonnay JM Puizillou S Antoun S Demirdjian OA El, et al. 2002 Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution Ann Oncol. 13 267 272 11886004 10.1093/annonc/mdf019 1:STN:280:DC%2BD387ltl2gtg%3D%3D
15. N Piché FA Leblond L Sidéris V Pichette P Drolet LP Fortier, et al. 2011 Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model Ann Surg. 254 138 144 21494122 10.1097/SLA.0b013e3182193143
16. P Ortega-Deballon O Facy S Jambet G Magnin E Cotte JL Beltramo, et al. 2010 Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques Ann Surg Oncol. 17 1957 1963 20143265 10.1245/s10434-010-0937-z